Cationizing Lugdunin through Trp³ Hydrophobic Fine-Tuning and Cationic Side Chain Engineering

Area of Science:

• Antimicrobial drug discovery
• Peptide chemistry
• Infectious disease research

Background:

• Lugdunin is a rare cyclic peptide antibiotic with a unique structure.
• Its clinical application is limited by inherent structural constraints.
• Developing novel antibiotics against resistant pathogens is a global health priority.

Purpose of the Study:

• To overcome Lugdunin's limitations through chemical modification.
• To synthesize and evaluate novel cationic Lugdunin derivatives for enhanced antibacterial activity.
• To investigate the mechanism of action of modified Lugdunin.

Main Methods:

• Hydrophobic fine-tuning using Tryptophan3 (Trp3).
• Cationic engineering to create Lugdunin derivatives.
• In vitro antibacterial assays against pathogens like Methicillin-resistant Staphylococcus aureus (MRSA).
• Mechanism of action studies, including membrane disruption and reactive oxygen species (ROS) analysis.
• In vivo efficacy testing in a mouse model of MRSA pneumonia.

Main Results:

• A novel cationic Lugdunin derivative, W17, was synthesized.
• W17 exhibited potent activity against MRSA with rapid bactericidal effects.
• W17 demonstrated a low propensity for resistance development.
• The mechanism involves a synergistic dual action: membrane disruption and ROS cascade.
• W17 showed excellent stability, biocompatibility, and therapeutic efficacy in a preclinical mouse model.

Conclusions:

• Cationization of Lugdunin significantly enhances its antibacterial properties and broadens its clinical applicability.
• W17 represents a promising new antibiotic candidate for treating resistant bacterial infections.
• The modified Lugdunin derivatives offer a viable strategy for developing next-generation antibiotics.